Theravac Biologics

TheraVac Biologics

Active Immunotherapies for Chronic and
Neurodegenerative Diseases

TheraVac Biologics is developing novel immunotherapies for diseases caused by misfolded protein aggregates and/or chronic inflammation.
ABOUT THERAVAC

Our Vision

The current therapeutic approaches have limited efficacy and will not be able to satisfy the increasing demand for treatment of chronic aging-related diseases including Alzheimer’s.

Our Mission

At TheraVac Biologics, we are aiming to develop safe and effective immunotherapies for treatment of chronic and neurodegenerative conditions including Alzheimer’s disease.

TheraVac’s Platform Technology

Offering safe, inexpensive, and effective immunotherapies

Platform

Multivalent display of immunogenic peptides on the surface of virus-like particles (VLPs)

Advantage

Elicits strong immune response with no requirements for using pro-inflammatory adjuvants

Regulatory Approval

VLP-based vaccines have been approved by FDA: Gardasil® and Recombinovax HB®

Our lead biologics, TV-301 and TV-202 target key pathways in Alzheimer’s pathology

Offering safe, inexpensive, and effective immunotherapies

NLRP3: nucleotide-binding domain, leucine-rich–containing family, pyrin domain–containing-3
ASC: apoptosis-associated speck-like protein containing a caspase-recruitment domain

Our biologics development pipeline

offering safe, inexpensive, and effective immunotherapies
TV-301 / Alzheimer’s disease
(prodromal to mild) 80%
TV-301 / Traumatic Brain Injury
45%
TV-202 / Frontotemporal dementia*
75%
TV-202 / Multiple sclerosis (PPMS)
45%
TV-202 / Non-CNS, TBD
45%
TV-100 / TBD
35%
*Orphan disease
TV-100: inflammasome blocking antibody
TBD: to be disclosed
Our Team

Ali Riazi, PhD

Co-founder and CEO

Laurent Balenci, PhD, MBA

Co-founder and COO

Nikki Maphis, PhD

Senior scientist
Vaccines Program

Kiran Bhaskar, PhD

Scientific Co-founder
UNM- Co-Director, Alzheimer’s
Disease Research Center

Bryce Chackerian, PhD

Scientific Co-founder
UNM- Professor and Vice Chair
Molecular Genetics

Mark Lievonen, CM, FCPA, FCA

Business Advisor
Former President of Sanofi Pasteur Limited

Saeed Karima, PhD

Scientific Advisor
Clinical biochemist

Aleksei Evteshin, BBA

Finance Director/Advisor

Krista Lanctot, PhD

Senior Scientist, Sunnybrook
Research Institute